F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical laboratories, institutions, guilds and medical federations have taken on the task of designing programs to end health illiteracy in order to have informed, educated, knowledgeable and empowered communities where their health and wellbeing are concerned. 19 September 2024
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
French biopharmaceutical company Genticel has recruited Sophie Olivier as chief medical officer to lead the clinical development of its pipeline, in particular the ProCervix Phase II trial. 4 March 2014
Australian biotech company Novogen has announced the appointments of new board members and a strategic advisor to support its transition into a clinical-stage company with a growing US presence and an investor base in the USA and Australia. 4 March 2014
Executives are moving back to an ‘ex-directory’ world, where smaller, restricted networks are of the highest value, according to RSA, a global life sciences executive search and interim management specialist. 3 March 2014
Australian biotechnology firm Phosphagenics has appointed biotech industry veterans Lawrence Gozlan, Nathan Drona and Geert Cauwenbergh as non-executive directors, with Mr Gozlan assuming the role of Chairman of the Board on an interim basis. 3 March 2014
Belgium’s largest drugmaker, UCB, yesterday announced a succession plan for its chief excecutive, Roch Doliveux, saying that Jean-Christophe Tellier, currently executive vice president, Biopharma Brands and Solutions, will be appointed chief executive-elect and chairman of the executive committee as of March 1, 2014. 21 February 2014
Germany’s Merck KGaA has appointed Simon Sturge to head the biosimilars unit, effective March 1, succeeding Thierry Hulot, who created the biosimilars unit and took over responsibility for Global Manufacturing & Supply for the Merck Serono division at the end of last year. 20 February 2014
US drug developer Inovio Pharmaceuticals has expanded its senior management team with two appointments to help advance the company's growing pipeline of preclinical and clinical DNA vaccines. 18 February 2014
US biotech firm Biogen Idec has announced today that chairman of the board William Young, known as Bill, will retire from the company’s Board of Directors, effective at the company’s 2014 annual meeting of stockholders. 17 February 2014
Ireland-headquartered drugmaker Shire (LSE: SHP) has announced that Graham Hetherington, chief financial officer, has decided to step down from the company. 13 February 2014
Australia-based biotech company Alchemia has announced the appointment of Santo Costa as non-executive chairman of the Board of Directors, effective March 1. 11 February 2014
The pharmaceutical market is changing, says Georg Toufar, chief marketing officer of Mundipharma International, in an exclusive article for The Pharma Letter, providing some insight on how to deal with these changes. 11 February 2014
‘Momentum’ is the word which best describes 2013, according to AstraZeneca’s chief executive Pascal Soriot who commented on the firm’s year-end results at a media briefing in London this morning. 6 February 2014
A UK-based mobile human monitoring company is making waves in health care as it aims to revolutionize the way clinical trial data is collected. 4 February 2014
The founder of Douglas Pharmaceuticals, Sir Graeme Douglas, has announced his retirement as the company’s managing director, effective February 1. 4 February 2014
US generics major Actavis, which now has its headquarters in Ireland, has announced a realignment of its global strategic business structure to maximize the company's newly strengthened position as a leading specialty pharmaceutical developer, manufacturer and marketer, and to enhance Actavis' position for continued long-term growth. 1 February 2014